Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates
Identifieur interne : 002111 ( Istex/Corpus ); précédent : 002110; suivant : 002112Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates
Auteurs : Jarema Kochan ; Helios MurialdoSource :
- Virology [ 0042-6822 ] ; 1983.
English descriptors
- Teeft :
- Active intermediates, Active proheads, Aliquot, Assay, Bacteriophage, Bacteriophage lambda, Bacteriophage lambda prohead, Bacteriophage lambda prohead assembly, Becker, Beckman ultracentrifuge, Biological activity, Casjens, Cell extracts, Column elution conditions, Complementation, Complementation reaction, Extract, Ferrucci, Final volume, Fraction number, Gene products, Genes groel, Glycerol gradients, Gpgroel, Gpnu3, Groe, Groe functions, Groel, Hendrix, Hohn, Kochan, Lambda, Lambda prohead assembly, Liquid nitrogen, Marker rescue, Molecular nature, Monomeric, Morphogenesis, Murialdo, Mutation, Nacl, Phage, Phage lambda, Polymer, Proc, Prohead, Prohead assembly, Proheads, Radioactively, Room temperature, Sedimentation, Small oligomeric, Supernatant, Velocity sedimentation, Velocity sedimentation analysis, Water bath.
Abstract
Abstract: The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes B, C, Nu3, and E, as well as the E. coli genes groEL and groES. It has been previously shown that extracts prepared from cells infected with a λ C−E− mutant accumulate biologically active gpB and gpNu3 (Murialdo, H., and Becker, A., J. Mol. Biol. 125, 57–74 (1978)). To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads in vitro. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.
Url:
DOI: 10.1016/0042-6822(83)90537-8
Links to Exploration step
ISTEX:D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title><author><name sortKey="Kochan, Jarema" sort="Kochan, Jarema" uniqKey="Kochan J" first="Jarema" last="Kochan">Jarema Kochan</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</mods:affiliation></affiliation></author><author><name sortKey="Murialdo, Helios" sort="Murialdo, Helios" uniqKey="Murialdo H" first="Helios" last="Murialdo">Helios Murialdo</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4</idno><date when="1983" year="1983">1983</date><idno type="doi">10.1016/0042-6822(83)90537-8</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002111</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002111</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title><author><name sortKey="Kochan, Jarema" sort="Kochan, Jarema" uniqKey="Kochan J" first="Jarema" last="Kochan">Jarema Kochan</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</mods:affiliation></affiliation></author><author><name sortKey="Murialdo, Helios" sort="Murialdo, Helios" uniqKey="Murialdo H" first="Helios" last="Murialdo">Helios Murialdo</name><affiliation><mods:affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="ISSN">0042-6822</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1983">1983</date><biblScope unit="volume">131</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="100">100</biblScope><biblScope unit="page" to="115">115</biblScope></imprint><idno type="ISSN">0042-6822</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0042-6822</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Active intermediates</term><term>Active proheads</term><term>Aliquot</term><term>Assay</term><term>Bacteriophage</term><term>Bacteriophage lambda</term><term>Bacteriophage lambda prohead</term><term>Bacteriophage lambda prohead assembly</term><term>Becker</term><term>Beckman ultracentrifuge</term><term>Biological activity</term><term>Casjens</term><term>Cell extracts</term><term>Column elution conditions</term><term>Complementation</term><term>Complementation reaction</term><term>Extract</term><term>Ferrucci</term><term>Final volume</term><term>Fraction number</term><term>Gene products</term><term>Genes groel</term><term>Glycerol gradients</term><term>Gpgroel</term><term>Gpnu3</term><term>Groe</term><term>Groe functions</term><term>Groel</term><term>Hendrix</term><term>Hohn</term><term>Kochan</term><term>Lambda</term><term>Lambda prohead assembly</term><term>Liquid nitrogen</term><term>Marker rescue</term><term>Molecular nature</term><term>Monomeric</term><term>Morphogenesis</term><term>Murialdo</term><term>Mutation</term><term>Nacl</term><term>Phage</term><term>Phage lambda</term><term>Polymer</term><term>Proc</term><term>Prohead</term><term>Prohead assembly</term><term>Proheads</term><term>Radioactively</term><term>Room temperature</term><term>Sedimentation</term><term>Small oligomeric</term><term>Supernatant</term><term>Velocity sedimentation</term><term>Velocity sedimentation analysis</term><term>Water bath</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes B, C, Nu3, and E, as well as the E. coli genes groEL and groES. It has been previously shown that extracts prepared from cells infected with a λ C−E− mutant accumulate biologically active gpB and gpNu3 (Murialdo, H., and Becker, A., J. Mol. Biol. 125, 57–74 (1978)). To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads in vitro. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>murialdo</json:string><json:string>bacteriophage</json:string><json:string>lambda</json:string><json:string>gpgroel</json:string><json:string>prohead</json:string><json:string>becker</json:string><json:string>gpnu3</json:string><json:string>phage</json:string><json:string>hohn</json:string><json:string>proheads</json:string><json:string>hendrix</json:string><json:string>groe</json:string><json:string>radioactively</json:string><json:string>complementation</json:string><json:string>bacteriophage lambda</json:string><json:string>biological activity</json:string><json:string>prohead assembly</json:string><json:string>morphogenesis</json:string><json:string>kochan</json:string><json:string>proc</json:string><json:string>ferrucci</json:string><json:string>polymer</json:string><json:string>mutation</json:string><json:string>groel</json:string><json:string>aliquot</json:string><json:string>monomeric</json:string><json:string>casjens</json:string><json:string>velocity sedimentation analysis</json:string><json:string>nacl</json:string><json:string>phage lambda</json:string><json:string>velocity sedimentation</json:string><json:string>room temperature</json:string><json:string>active proheads</json:string><json:string>bacteriophage lambda prohead assembly</json:string><json:string>cell extracts</json:string><json:string>gene products</json:string><json:string>sedimentation</json:string><json:string>extract</json:string><json:string>assay</json:string><json:string>marker rescue</json:string><json:string>glycerol gradients</json:string><json:string>complementation reaction</json:string><json:string>supernatant</json:string><json:string>small oligomeric</json:string><json:string>bacteriophage lambda prohead</json:string><json:string>lambda prohead assembly</json:string><json:string>beckman ultracentrifuge</json:string><json:string>groe functions</json:string><json:string>active intermediates</json:string><json:string>liquid nitrogen</json:string><json:string>final volume</json:string><json:string>molecular nature</json:string><json:string>fraction number</json:string><json:string>column elution conditions</json:string><json:string>genes groel</json:string><json:string>water bath</json:string></teeft></keywords><author><json:item><name>Jarema Kochan</name><affiliations><json:string>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</json:string></affiliations></json:item><json:item><name>Helios Murialdo</name><affiliations><json:string>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</json:string></affiliations></json:item></author><arkIstex>ark:/67375/6H6-B97ZHG15-D</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Full-length article</json:string></originalGenre><abstract>Abstract: The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes B, C, Nu3, and E, as well as the E. coli genes groEL and groES. It has been previously shown that extracts prepared from cells infected with a λ C−E− mutant accumulate biologically active gpB and gpNu3 (Murialdo, H., and Becker, A., J. Mol. Biol. 125, 57–74 (1978)). To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads in vitro. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.</abstract><qualityIndicators><score>8.824</score><pdfWordCount>6784</pdfWordCount><pdfCharCount>42315</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>16</pdfPageCount><pdfPageSize>504 x 720 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>152</abstractWordCount><abstractCharCount>998</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title><pmid><json:string>6228056</json:string></pmid><pii><json:string>0042-6822(83)90537-8</json:string></pii><genre><json:string>research-article</json:string></genre><serie><title>Proc. Nat. Acad. Sci. USA</title><language><json:string>unknown</json:string></language><volume>72</volume><pages><first>581</first><last>585</last></pages></serie><host><title>Virology</title><language><json:string>unknown</json:string></language><publicationDate>1983</publicationDate><issn><json:string>0042-6822</json:string></issn><pii><json:string>S0042-6822(00)X0644-7</json:string></pii><volume>131</volume><issue>1</issue><pages><first>100</first><last>115</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>1983</json:string><json:string>30s</json:string></date><geogName></geogName><orgName><json:string>Department of Pathology, Columbia University</json:string><json:string>Canada Building, Received</json:string><json:string>Medical Research Council of Canada</json:string><json:string>National Institutes of Health</json:string></orgName><orgName_funder><json:string>Medical Research Council of Canada</json:string><json:string>National Institutes of Health</json:string></orgName_funder><orgName_provider></orgName_provider><persName><json:string>M. Gold</json:string><json:string>M. Buchwald</json:string><json:string>Wendy L. Fife</json:string><json:string>B.Nu</json:string><json:string>A. Becker</json:string></persName><placeName><json:string>York</json:string><json:string>Velocity</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>Becker et aL, 1977</json:string><json:string>Boklage et al, 1973</json:string><json:string>Murialdo and Hohn, 1974</json:string><json:string>Kaiser and Masuda, 1973</json:string><json:string>Shaw, 1981</json:string><json:string>Becker 1979; Ferrucci and Murialdo, 1981</json:string><json:string>Kaiser and Masuda (1973)</json:string><json:string>Yanofsky and Ito (1966)</json:string><json:string>Cas- gpB and gpB* (a cleaved form of gpB jens et al, 1972</json:string><json:string>Murialdo and Ray, 1975</json:string><json:string>Hohn and Hohn, 1974</json:string><json:string>Kaiser et al, 1974, 1975</json:string><json:string>Tsui and Hendrix, 1980</json:string><json:string>Hendrix, 1971</json:string><json:string>Casjens, 1974</json:string><json:string>Hohn (Murialdo and Becker, 1978a</json:string><json:string>C-Nz&-E-, 1978</json:string><json:string>Hendrix and Jara and Murialdo, 1975</json:string><json:string>Murialdo and Siminovitch, 1971</json:string><json:string>Ptashne, 1967</json:string><json:string>Tsui and Hendrix (1980)</json:string><json:string>Murialdo and Becker, 1977,1978a</json:string><json:string>Tilly et ab, 1981</json:string><json:string>Hohn et aL, 1975</json:string><json:string>Hendrix and Tsui, 1978</json:string><json:string>Kaiser et al, 1975</json:string><json:string>Georgopoulos and Hohn, 1978</json:string><json:string>Zachary et al, 1976</json:string><json:string>Hendrix and Casjens, 1975</json:string><json:string>Hohn et al., 1975</json:string><json:string>Hohn et al, 1974</json:string><json:string>Tilly et aL, 1981</json:string><json:string>Fuerst and Becker (1978a)</json:string><json:string>Murialdo and Becker, 1978b</json:string><json:string>Hendrix, 1979</json:string><json:string>Murialdo, 1979</json:string><json:string>Hohn et al, 1979</json:string><json:string>Georgopoulos et al, 1973</json:string><json:string>Murialdo and Becker, 1977</json:string><json:string>Hohn et to be degraded during its exit from the al, 1974</json:string><json:string>Hendrix and Casjens, 1974</json:string><json:string>McClure and Gold (1973)</json:string><json:string>Georgopoulos et al., 1973</json:string><json:string>Murialdo and Becker, 1978a</json:string><json:string>Murialdo and Becker (1978a)</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-B97ZHG15-D</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - virology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Virology</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences biologiques fondamentales et appliquees. psychologie</json:string><json:string>4 - microbiologie</json:string></inist></categories><publicationDate>1983</publicationDate><copyrightDate>1983</copyrightDate><doi><json:string>10.1016/0042-6822(83)90537-8</json:string></doi><id>D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a">Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher scheme="https://scientific-publisher.data.istex.fr">ELSEVIER</publisher><availability><licence><p>elsevier</p></licence></availability><p scheme="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M"></p><date>1983</date></publicationStmt><notesStmt><note type="research-article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</note><note type="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note><note>Paper I in this series is Murialdo (1979).</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title><author xml:id="author-0000"><persName><forename type="first">Jarema</forename><surname>Kochan</surname></persName><note type="biography">Present address: Department of Pathology, Columbia University, 630 West 168th Street, New York, N. Y. 10032.</note><affiliation>Present address: Department of Pathology, Columbia University, 630 West 168th Street, New York, N. Y. 10032.</affiliation><affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Helios</forename><surname>Murialdo</surname></persName><note type="biography">To whom reprint requests should be addressed.</note><affiliation>To whom reprint requests should be addressed.</affiliation><affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</affiliation></author><idno type="istex">D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4</idno><idno type="ark">ark:/67375/6H6-B97ZHG15-D</idno><idno type="DOI">10.1016/0042-6822(83)90537-8</idno><idno type="PII">0042-6822(83)90537-8</idno></analytic><monogr><title level="j">Virology</title><title level="j" type="abbrev">YVIRO</title><idno type="pISSN">0042-6822</idno><idno type="PII">S0042-6822(00)X0644-7</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1983"></date><biblScope unit="volume">131</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="100">100</biblScope><biblScope unit="page" to="115">115</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1983</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes B, C, Nu3, and E, as well as the E. coli genes groEL and groES. It has been previously shown that extracts prepared from cells infected with a λ C−E− mutant accumulate biologically active gpB and gpNu3 (Murialdo, H., and Becker, A., J. Mol. Biol. 125, 57–74 (1978)). To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads in vitro. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.</p></abstract></profileDesc><revisionDesc><change when="1983">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="fla"><item-info><jid>YVIRO</jid><aid>83905378</aid><ce:pii>0042-6822(83)90537-8</ce:pii><ce:doi>10.1016/0042-6822(83)90537-8</ce:doi><ce:copyright type="unknown" year="1983"></ce:copyright></item-info><head><ce:article-footnote><ce:label>☆</ce:label><ce:note-para>Paper I in this series is <ce:cross-ref refid="BIB28">Murialdo (1979)</ce:cross-ref>.</ce:note-para></ce:article-footnote><ce:title>Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</ce:title><ce:author-group><ce:author><ce:given-name>Jarema</ce:given-name><ce:surname>Kochan</ce:surname><ce:cross-ref refid="FN1"><ce:sup>2</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Helios</ce:given-name><ce:surname>Murialdo</ce:surname><ce:cross-ref refid="COR1"><ce:sup>3</ce:sup></ce:cross-ref></ce:author><ce:affiliation><ce:textfn>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</ce:textfn></ce:affiliation><ce:correspondence id="COR1"><ce:label>3</ce:label><ce:text>To whom reprint requests should be addressed.</ce:text></ce:correspondence><ce:footnote id="FN1"><ce:label>2</ce:label><ce:note-para>Present address: Department of Pathology, Columbia University, 630 West 168th Street, New York, N. Y. 10032.</ce:note-para></ce:footnote></ce:author-group><ce:date-received day="24" month="5" year="1983"></ce:date-received><ce:date-accepted day="5" month="8" year="1983"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes <ce:italic>B, C, Nu3</ce:italic>, and <ce:italic>E</ce:italic>, as well as the <ce:italic>E. coli</ce:italic> genes <ce:italic>groEL</ce:italic> and <ce:italic>groES</ce:italic>. It has been previously shown that extracts prepared from cells infected with a λ <ce:italic>C<ce:sup>−</ce:sup>E<ce:sup>−</ce:sup></ce:italic> mutant accumulate biologically active gpB and gpNu3 <ce:cross-ref refid="BIB30">(Murialdo, H., and Becker, A., <ce:italic>J. Mol. Biol.</ce:italic> <ce:bold>125</ce:bold>, 57–74 (1978))</ce:cross-ref>. To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads <ce:italic>in vitro</ce:italic>. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.</ce:simple-para></ce:abstract-sec></ce:abstract></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates</title></titleInfo><name type="personal"><namePart type="given">Jarema</namePart><namePart type="family">Kochan</namePart><affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</affiliation><description>Present address: Department of Pathology, Columbia University, 630 West 168th Street, New York, N. Y. 10032.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Helios</namePart><namePart type="family">Murialdo</namePart><affiliation>Department of Medical Genetics, University of Toronto, Medical Sciences Building, Toronto, Ontario M5S 1A8, Canada</affiliation><description>To whom reprint requests should be addressed.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="research-article" displayLabel="Full-length article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-1JC4F85T-7">research-article</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1983</dateIssued><copyrightDate encoding="w3cdtf">1983</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: The morphogenesis of bacteriophage λ proheads is under the control of the four phage genes B, C, Nu3, and E, as well as the E. coli genes groEL and groES. It has been previously shown that extracts prepared from cells infected with a λ C−E− mutant accumulate biologically active gpB and gpNu3 (Murialdo, H., and Becker, A., J. Mol. Biol. 125, 57–74 (1978)). To characterize the nature of these intermediates in prohead assembly, extracts prepared from these cells were fractionated by DEAF-cellulose chromatography as well as velocity sedimentation. Intermediates containing gpB were identified by SDS-polyacrylamide gel electrophoresis and by their ability to be assembled into biologically active proheads in vitro. The results indicate that the most abundant, biologically active intermediate (greater than 98% of the gpB activity) is a 25 S gpB-containing polymer. A second biologically active intermediate (about 1% of the total gpB activity) was identified as a gpB-gpgroEL complex.</abstract><note>Paper I in this series is Murialdo (1979).</note><relatedItem type="host"><titleInfo><title>Virology</title></titleInfo><titleInfo type="abbreviated"><title>YVIRO</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">1983</dateIssued></originInfo><identifier type="ISSN">0042-6822</identifier><identifier type="PII">S0042-6822(00)X0644-7</identifier><part><date>1983</date><detail type="volume"><number>131</number><caption>vol.</caption></detail><detail type="issue"><number>1</number><caption>no.</caption></detail><extent unit="issue-pages"><start>1</start><end>264</end></extent><extent unit="pages"><start>100</start><end>115</end></extent></part></relatedItem><identifier type="istex">D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4</identifier><identifier type="ark">ark:/67375/6H6-B97ZHG15-D</identifier><identifier type="DOI">10.1016/0042-6822(83)90537-8</identifier><identifier type="PII">0042-6822(83)90537-8</identifier><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/6H6-B97ZHG15-D/record.json</uri></json:item></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002111 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002111 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:D8BD8875BE16FEF63EAFBFCA7454F724EDA84EA4
|texte= Early intermediates in bacteriophage lambda prohead assembly II. Identification of biologically active intermediates
}}
| This area was generated with Dilib version V0.6.33. |  |